This ongoing multicentre prospective phase I/II trial enrolled 74 consecutive patients from 22 centres worldwide with severe autoimmune disease, 35 with rheumatological disorders, 31 with neurological, five with haematological and three with vasculitides. They were treated with autologous peripheral blood or bone marrow transplants according to predetermined criteria. Two patients died after mobilisation before transplant. Seventy-two patients were given 73 transplants, seven bone marrow, and 66 mobilised peripheral blood stem cell transplants. The graft was manipulated to remove T and/or B cells in 43 cases. All 73 transplants engrafted. Five patients died of transplant-related complications: two from bleeding, three from infections. Two patients died of progressive disease. The transplant-related mortality at 1 year of 9% (1-17%; 95% CI) is comparable to the transplant-related mortality of 6% (3-9%; 95% CI) in patients transplanted during the same period in Europe for non-Hodgkin's lymphoma in sensitive relapse (P = 0.39). Sixty patients are evaluable for response, 40 patients (65%) showed some improvement in their disease. Haematopoietic stem cell transplants are feasible for patients with severe refractory autoimmune disease. Transplant-related mortality is comparable to results in patients with non-Hodgkin's lymphoma in responsive relapse. Two-thirds of the patients show at least some response. These preliminary data are promising. Although associated with considerable risk, randomised trials comparing autologous stem cell transplants to conventional therapy are warranted. Keywords: autoimmune disease; stem cell; toxicity; mortality; bone marrow Correspondence: Prof A Tyndall, University Rheumatology Clinic, Felix Platter Hospital, CH-4012 Basel, Switzerland Received 7 December 1998; accepted 9 May 1999 Theoretical considerations, preclinical animals models and anecdotal evidence from patients transplanted for malignancy with coincidental autoimmune disease support the concept that the natural course of severe autoimmune disease may be altered by intensive immunoablation and stem cell support, eg autologous haematopoietic stem cell transplantation. Eradication of autoreactive cells by the conditioning regimen, redistribution of an altered cellular and humoral immunological network or thymic re-education are discussed as potential mechanisms for response.
Theoretical considerations, preclinical animals models and anecdotal evidence from patients transplanted for malignancy with coincidental autoimmune disease support the concept that the natural course of severe autoimmune disease may be altered by intensive immunoablation and stem cell support, eg autologous haematopoietic stem cell transplantation. Eradication of autoreactive cells by the conditioning regimen, redistribution of an altered cellular and humoral immunological network or thymic re-education are discussed as potential mechanisms for response. [1] [2] [3] [4] [5] [6] Before 1995, no transplants were performed for isolated autoimmune disease. A joint committee of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT) then initiated a phase I/II study to assess feasibility, mortality and preliminary response of such an approach. [7] [8] [9] This was joined by several North American and Australian centres and is referred to as the International Autoimmune Disease Stem Cell Project. This report summarises the initial experience.
Methods

Trial design
The basic concept of this open, multicentre, phase I/II-like study was designed and published by a joint committee of the EULAR and EBMT. 8, 9 Guidelines generated from this consensus statement were provided to participating centres, in particular relating to patient selection (see eligibility criteria below) and use of a restricted number of protocols. The data registry did not strictly control adherence to the protocol. The detailed treatment plans for individual patients followed local institutional protocols. All patients registered at the International Stem Cell Project data base up to 1 June 1998 are included, all are consecutive patients, Twenty-two centres in 12 countries took part in this pilot phase (listed in detail in the Appendix).
Eligibility criteria
Patients with severe neurological, rheumatological or haematological autoimmune diseases were eligible when they had severe life-or organ-threatening disease, refractory to standard treatment, mostly consisting of immunosuppression with a single agent. Patients with severe irreversible end organ damage were not considered to be suitable transplant candidates. Evaluation of eligible patients by two independent specialists in the field, informed consent and approval by the local ethical committee or institutional review board were part of the protocol. Informed consent included the information that the expected transplant-related mortality was 3-5%, and that the chance of dying or being severely disabled from the AD was significantly higher.
Transplant techniques
Peripheral blood stem cells were mobilised with standard techniques for 66 patients, by G-CSF alone (15 patients), cyclophosphamide (Cy) + G-CSF ± other (38 patients), Cy + GM-CSF (nine patients) or by cyclophosphamide alone (seven patients); bone marrow was used in seven patients, primarily in children. Four main conditioning regimens were used as listed in Table 1 : 200 mg/kg Cy ± antilymphocyte globulin (ATG) or monoclonal antibodies (27 patients), BEAM polychemotherapy (BCNU, VP-16, Arac and melphalan) ± ATG (29 patients), busulfan and cyclophosphamide (BuCy) (six patients) or Cy and total body irradiation (Cy/Rx) ± ATG (seven patients). Other regimens were used in three patients.
TBI doses were 8 Gy in adults and 4 Gy in children. ATG in European centres was mostly 10 or 20 mg/kg body weight and in the USA, 30 or 90 mg/kg body weight. The majority of centres used 10 g/kg body weight/day G-CSF for mobilising CD34 cells.
Graft manipulation
Graft manipulation varied from team to team and is listed in Table 1 . No attempts were made to remove T or B cells for 28 transplants. CD34-positive selection alone was done for 27 grafts. CD34 selection plus T cell depletion for three, CD34 selection plus T and B cell depletion for eight, T cell depletion alone for four patients and other methods for one patient.
Outcome measures
Outcomes studied were mobilisation efficiency, toxicity of peripheral stem cell mobilisation, transplant-related mortality and overall survival using published criteria. 10 Data on response are limited. For this analysis, response was defined for the main indications as follows: for multiple sclerosis as improvement by at least one point on the Kurtzke (EDSS) scale. 11 In rheumatological disorders, global assessments using measurements such as skin scores (systemic sclerosis), joint counts (rheumatoid arthritis, organ involvement and laboratory parameters (acute phase reactants, autoantibodies, etc) were categorised as response vs no response. 12 In haematological diseases, response was defined as normalisation of peripheral blood counts.
These 72 patients with AD were compared to 391 patients transplanted between 1995 and 1997 with an autologous haematopoietic stem cell transplant for non-Hodgkin's lymphoma in sensitive relapse and reported to the EBMT lymphoma registry. This includes 38 patients with bone marrow, 346 patients with peripheral blood and seven patients with combined bone marrow and peripheral blood stem cell autografts. One hundred and seven patients had low, 103 intermediate and 181 high grade lymphoma.
Statistical methods
Transplant-related mortality and overall survival were calculated using the Kaplan-Meier estimator. 13 The 95% confidence interval was approximated using two times the standard error as calculated by the Greenwood formula.
14 The log rank test was used for comparison with lymphoma patients.
Results
Patients
Seventy-four patients, 27 male and 47 female, between ages 7 and 64 (median 39 years) were included. They are listed by disease in Table 1 . Thirty-five patients had rheumatological, 31 neurological, 5 haematological autoimmune disorders and three suffered from vasculitides.
Mobilisation
In 68 patients peripheral blood mobilisation was attempted. One patient with systemic sclerosis and pulmonary artery hypertension died during neutropenia of septicaemia and heart failure, one patient with systemic sclerosis died of a cardiac event after successful mobilisation, thought to be related to the underlying condition. The relation of this event with the procedure remains open. Of about 900 patients mobilised during the same time period in the same centres for leukaemias, lymphomas or solid tumours, four patients died during mobilisation, all after priming with 7 g/m 2 of cyclophosphamide. One heavily pretreated patient with multiple sclerosis failed to mobilise peripheral blood stem cells after a first attempt with reduced dose cyclophosphamide, 2 g/m 2 , and G-CSF. She was successfully mobilised with cyclophosphamide 4 g/m 2 and an elevated G-CSF dose. One patient with systemic lupus erythematosus showed recurrence of vasculitis during mobilisation. Mobilisation was uneventful in all other cases without reported major disease exacerbations or unexpected side-effects. In some RA cases, minor worsening of joint symptoms was reported, easily controlled with anti-inflammatory treatment (J Snowden, personal communication).
The currently used data record forms do not provide for disease exacerbation details, and are under revision, together with a prospective study relating to mobilisation and transplant-related disease exacerbations. 
Procedure-related mortality
Two patients died following mobilisation before transplantation, considered to be possibly procedure related. In the remaining 72 patients, 73 transplants were performed. Seven of these patients have died, corresponding to a survival probability at 1 year of 87% (77-97%, 95% CI). Median follow-up time of surviving patients is 308 days (range 25-1026 days). Five patients died of transplantrelated complications, three infections and two bleeding complications. One patient with multiple sclerosis died of parainfluenza virus pneumonia on day 20 post transplant, one patient with multiple sclerosis of disseminated aspergillus infection on day 58, one patient with rheumatoid arthritis of staphylococcal septicaemia and lung cancer (coincidentally diagnosed at death), one patient with systemic sclerosis of pulmonary haemorrhage on day 11 and one patient with systemic sclerosis of CNS haemorrhage on day 40. The transplant-related mortality of 9% (1-17%, 95% CI) is comparable to the transplant-related mortality of 6% (3-9%, 95% CI) at 1 year of the 391 patients with lymphoma (P = 0.39) (Figure 1 ).
Response
Sixty of the 72 patients (81%) are evaluable for response, 12 are either too early or unclear. The response rate is illustrated in Table 1 . In 40 patients (65%) some response as defined above was observed. To date, 14 patients have progressed or relapsed; two patients have died of progressive disease, one with systemic sclerosis and one patient with amyotrophic lateral sclerosis.
Discussion
These preliminary data from patients with autoimmune diseases transplanted with autologous haematopoietic stem cells following intensive immunoablation show that the procedure is feasible. Transplant-related mortality is com- parable to patients transplanted for NHL in sensitive relapse, an established indication. 15 Data are still limited, follow-up is short and the patient population is heterogeneous. In addition, stricter definitions of improvement or progression in such patients need to be developed and standardised. Despite these limitations some conclusions can be drawn and the outstanding issues delineated: there are no obvious clues that mobilisation, harvesting, transplant procedure and toxicity in patients with autoimmune disease are different from patients treated for other indications. Sufficient cells can be mobilised using standard regimens. Exacerbations of autoimmune disease, one of the potential concerns of mobilisation and observed in a minority of patients with rheumatoid arthritis have been an uncommon event. 16 This multicentre study allows a preliminary assessment of the mortality to be expected with the procedure. None of the approximately 30 patients reported in detail in publications died. [17] [18] [19] [20] [21] [22] [23] [24] In contrast, nine patients of the 74 in this phase I/II pilot study have died, two even before the transplant. Mortality during mobilisation is rarely reported. Observational analyses do not include such patients, as no data are collected from patients not given transplants. At some centres, patients are referred for stem cell collection only. Mobilisation procedures might have been initiated elswhere. It is to be noted that the two patients with lethal complications during mobilisation in this series had systemic sclerosis, a disease associated with pulmonary and cardiac involvement. The four patients with lethal complications during mobilisation for other diseases had received a high cyclophosphamide dose of 7 g/m 2 , previously reported to be associated with a higher rate of complications. 25 Three transplanted patients succumbed to infections following T cell-depleted autologous stem cell transplants, two from bleeding complications. The limited number of patients precludes a risk factor analysis, deaths were observed in different disease categories, multiple sclerosis, systemic sclerosis and rheumatoid arthritis. There are no clues that risk factors for procedure-related mortality might be different in autoimmune disease.The well known major risk factors in stem cell transplants are age of the patient, stage of the disease at the time of the transplant and intensity of conditioning. [26] [27] [28] The observed incidence of procedure-related mortality underlines the need for careful patient selection and for restriction of the procedure to experienced transplant centres.
The role of T cell depletion remains a matter of debate. [1] [2] [3] [4] 7, 8, 29 Although it was performed in the majority of cases, conclusive evidence of benefit is missing. Failures to respond in patients with depleted grafts and reponses in patients given unmanipulated grafts suggest that disease status may be more relevant than graft manipulation. This fits with observations in autologous transplants for malignant disease. An advantage of purging is postulated in patients with limited and responsive disease. 30, 31 Purging is of no benefit in patients without residual disease and in patients with disease refractory to treatment. Purging can be favoured in malignant disease with the argument, that reinfusion of malignant cells would never be of any benefit. In contrast, in autoimmune disease, T or B cell depletion may be a disadvantage. Their removal may induce a pro-longed period of lymphopenia with its inherent immune deficiency and susceptibility to infections.
Assessment of response at present remains difficult. Some response was reported in two-thirds of evaluable patients, even a clinical and immunological complete response in some cases. However, follow-up is short, and criteria for response and relapse have not yet been fully defined. This relates in particular to progressive multiple sclerosis where improvements have been described, but where previously no treatment has proven effective. To date, no particular conditioning regimen or treatment approach can be favoured.
These preliminary, cautiously optimistic, data of haematopoietic stem cell transplants in autoimmune disease show that this approach is feasible and may result in complete and sustained responses in some patients. The transplantrelated mortality reported here confirms the concept that patient selection is the most critical issue at this early phase. The optimal strategies, optimal patient selection and details of best techniques, now need to be defined. The data being generated and carefully collected provide a valuable resource to plan such a treatment option better, given its intrinsic potential toxicity. More important, an advantage of intensive immunoablation and autologous stem cell support compared to standard strategies needs to be documented and comparative studies are warranted. The data from this study give an estimate of the risks to be expected and provide the basis for planning such prospective randomised comparative trials.
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